You have 9 free searches left this month | for more free features.

CPG-oligonucleotide

Showing 1 - 25 of 183

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-OX40 Antibody BMS 986178
  • TLR9 Agonist SD-101
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jun 13, 2022

Plague, Pneumonic, Plague, Vaccine-Preventable Diseases Trial in United States (rF1V vaccine and CpG 1018® adjuvant, rF1V

Recruiting
  • Plague, Pneumonic
  • +2 more
  • rF1V vaccine and CpG 1018® adjuvant
  • rF1V vaccine
  • Huntsville, Alabama
  • +4 more
Aug 16, 2022

Lung Cancer, Hepatocellular Carcinoma, Solid Tumor Trial in Guangzhou (CpG-ODN)

Recruiting
  • Lung Cancer
  • +2 more
  • CpG-ODN
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Jun 27, 2021

Mild Cognitive Impairment, Alzheimer Dementia Trial (CpG1018, Placebo)

Not yet recruiting
  • Mild Cognitive Impairment
  • Alzheimer Dementia
  • (no location specified)
Jan 3, 2023

Liver Metastasis Colon Cancer Trial (IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN)

Not yet recruiting
  • Liver Metastasis Colon Cancer
  • IRE plus checkpoint inhibitor
  • IRE plus Checkpoint Inhibitor plus CpG-ODN
  • (no location specified)
Sep 13, 2023

COVID-19 Trial in Kyiv, Vinnitsa (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline)

Terminated
  • COVID-19
  • CpG 1018/Alum-adjuvanted SCB-2019 vaccine
  • +2 more
  • Kyiv, Ukraine
  • +3 more
May 19, 2022

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

COVID-19 Trial in Adelaide (Advax-CpG55.2 adjuvanted recombinant spike protein)

Recruiting
  • COVID-19
  • Advax-CpG55.2 adjuvanted recombinant spike protein
  • Adelaide, South Australia, Australia
    ARASMI
Aug 15, 2022

COVID-19 Trial in Nedlands (SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant)

Completed
  • COVID-19
  • SCB-2019
  • +3 more
  • Nedlands, Western Australia, Australia
    Linear Clinical Research Ltd
Feb 17, 2022

Effectiveness of Standard Therapy of Acne Vulgaris

Completed
  • Acne Vulgaris
    • Jakarta Pusat, Jakarta, Indonesia
      dr.Cipto Mangunkusumo National Central General Hospital
    Aug 7, 2023

    Pain, Dementia Trial (Pain-CPG-EIT, Pain-CPG-Education Only)

    Not yet recruiting
    • Pain
    • Dementia
    • Pain-CPG-EIT
    • Pain-CPG-Education Only
    • (no location specified)
    May 12, 2023

    Tuberculosis Trial in Shanghai (Placebo, Low dose adjuvant, High dose adjuvant)

    Completed
    • Tuberculosis
    • Placebo
    • +4 more
    • Shanghai, Shanghai, China
      Shanghai Public Health clinical Center
    Mar 9, 2022

    Healthcare Worker, Hepatitis B Vaccine, Nonresponder Trial in Madison (Recombinant hepatitis B vaccine with CpG adjuvant)

    Recruiting
    • Healthcare Worker, Hepatitis B Vaccine, Nonresponder
    • Recombinant hepatitis B vaccine with CpG adjuvant
    • Madison, Wisconsin
      University of Wisconsin
    Jul 5, 2022

    Primary IgA Nephropathy Trial (RO7434656, Placebo)

    Not yet recruiting
    • Primary IgA Nephropathy
    • (no location specified)
    Mar 22, 2023

    Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)

    Recruiting
    • Solid Tumor
    • TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
    • Aldesleukin
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Jan 31, 2023

    COVID-19 Trial in Worldwide (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine)

    Recruiting
    • COVID-19
    • CpG 1018/Alum-adjuvanted SCB-2019 vaccine
    • +3 more
    • Alken, Belgium
    • +30 more
    Feb 7, 2022

    Clinical Practice Guidelines, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury) Trial in

    Completed
    • Clinical Practice Guidelines
    • +7 more
    • Telehealth-based strategy
    • Medellín, Antioquia, Colombia
      Universidad de Antioquia
    Nov 2, 2022

    Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

    Recruiting
    • Mantle Cell Lymphoma
    • +9 more
    • L-Bcl-2 antisense oligonucleotide
    • Augusta, Georgia
    • +2 more
    Nov 18, 2022

    Hepatitis B Trial in Baltimore, Falls Church (Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B])

    Withdrawn
    • Hepatitis B
    • Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
    • Baltimore, Maryland
    • +1 more
    Jul 19, 2022

    Bladder Cancer, Urothelial Carcinoma Trial in United States (OGX-427, Docetaxel)

    Completed
    • Bladder Cancer
    • Urothelial Carcinoma
    • Birmingham, Alabama
    • +34 more
    Jul 7, 2022

    Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

    Recruiting
    • Myeloid Malignancies
    • Lymphoid Malignancies
    • NK Cell enriched-DLI only
    • NK-DLI + DUK-CPG-001
    • Durham, North Carolina
      Duke University Health System
    Mar 8, 2022

    Covid19 Trial in Canada, United States (Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo)

    Active, not recruiting
    • Covid19
    • Low Dose of KBP-COVID-19
    • +2 more
    • West Palm Beach, Florida
    • +7 more
    Aug 15, 2022

    Rheumatoid Arthritis Trial in Canada, United States (ISIS 104838)

    Completed
    • Rheumatoid Arthritis
    • ISIS 104838
    • Birmingham, Alabama
    • +30 more
    Dec 1, 2022

    Antisense Oligonucleotide for Spinal Muscular Atrophy

    Recruiting
    • Spinal Muscular Atrophy
    • Beijing, Beijing, China
    • +2 more
    Jan 11, 2022